Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY004 in Adult r/r B-ALL
NCT06009107Phase 2Withdrawn
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
A Phase 2 trial of HY 004 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Juventas Cell Therapy Ltd.. Planned start Jun 2025; status: withdrawn.
02
Drugs
HY 004
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06009107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06009107.